{
  "id": "964d421ba2275dc0",
  "title": "uniQure N . V . Securities Fraud Class Action Result of FDA Approval Delay and 49 % Stock Decline - Investors may Contact Lewis Kahn , Esq , at Kahn Swick & Foti , LLC",
  "description": "20260214T040000Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "https://www.prnewswire.com/news-releases/uniqure-nv-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302688030.html",
  "published_at": "20260214T040000Z",
  "fetched_at": "2026-02-15T00:30:56.287245+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.prnewswire.com/news-releases/uniqure-nv-securities-fraud-class-action-result-of-fda-approval-delay-and-49-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302688030.html",
    "url_mobile": "",
    "title": "uniQure N . V . Securities Fraud Class Action Result of FDA Approval Delay and 49 % Stock Decline - Investors may Contact Lewis Kahn , Esq , at Kahn Swick & Foti , LLC",
    "seendate": "20260214T040000Z",
    "socialimage": "https://mma.prnewswire.com/media/2273998/2025_PR_SEC.jpg?p=facebook",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}